Community Schedule

You are currently viewing December 2024

1 results showing for: 'octocog alfa [recombinant factor viii] (advate)'

Octocog alfa [Recombinant factor VIII] (Advate)

[Xpharm]

Inj 250 iu vial
- Brand Fully subsidised brand. Advate
- Pharmacode2292696
- Subsidy $210.00
- Measure / Qty per 1
(Advate Inj 250 iu vial to be delisted 01 February 2025)

Inj 500 iu vial
- Brand Fully subsidised brand. Advate
- Pharmacode2292718
- Subsidy $420.00
- Measure / Qty per 1

Inj 1,000 iu vial
- Brand Fully subsidised brand. Advate
- Pharmacode2292726
- Subsidy $840.00
- Measure / Qty per 1

Inj 1,500 iu vial
- Brand Fully subsidised brand. Advate
- Pharmacode2292742
- Subsidy $1260.00
- Measure / Qty per 1
(Advate Inj 1,500 iu vial to be delisted 01 February 2025)

Inj 2,000 iu vial
- Brand Fully subsidised brand. Advate
- Pharmacode2292750
- Subsidy $1680.00
- Measure / Qty per 1

Inj 3,000 iu vial
- Brand Fully subsidised brand. Advate
- Pharmacode2292769
- Subsidy $2520.00
- Measure / Qty per 1

For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Rectangle page icon symoblising a PDF. PDF
A tick icon. Fully subsidised
An oval with the number 29 in it. Unapproved medicine under Section 29
An asterisk symbol. 3 or 6 months should be dispensed at once
Two duplicate pages icon. Click to copy
A triangle symbol. Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
OP Original pack
Sole Subsidised Supply